Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8515808 | 1.00 | BTN3A1 (0.36) | BTN3A1ALDH1A1 | |
| SCHEMBL7072799 | 0.90 | KMT2A (0.36) | BTN3A1ALDH1A1 | |
| SCHEMBL19820899 | 0.82 | BTN3A1 (0.36) | BTN3A1ALDH1A1 | |
| SCHEMBL19820900 | 0.82 | BTN3A1 (0.36) | BTN3A1 | |
| SCHEMBL17997136 | 0.82 | BTN3A1 (0.36) | BTN3A1 | |
| SCHEMBL17997135 | 0.82 | BTN3A1 (0.36) | BTN3A1ALDH1A1 | |
| SCHEMBL14616356 | 0.79 | BTN3A1 (0.35) | BTN3A1 | |
| SCHEMBL14616295 | 0.79 | BTN3A1 (0.35) | BTN3A1 | |
| SCHEMBL7478423 | 0.78 | BTN3A1 (0.34) | BTN3A1 | |
| SCHEMBL7478433 | 0.78 | BTN3A1 (0.34) | BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109666637-B | Application of Vgamma 9 Vdelta 2T and agonist thereof in treatment of hepatic fibrosis, liver cirrhosis and liver cancer | 清华大学 | 2023-04-11 | — | — | CN | disclosed |
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012071458-A1 | HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | BTN3A1 1453/4885ALDH1A1 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.